Deregulation of the CDX2-KLF4 axis in acute myeloid leukemia and colon cancer
Deregulation of the CDX2-KLF4 axis in acute myeloid leukemia and colon cancer |
|
https://doi.org/10.18632/oncotarget.896
Arefeh Rouhi,
and Stefan Fröhling
|
| 174-175 |
Unexpected Outcomes of CDK4/6 Inhibition
Unexpected Outcomes of CDK4/6 Inhibition |
|
https://doi.org/10.18632/oncotarget.912
Yoon Jong Choi,
and Piotr Sicinski
|
| 176-177 |
Signaling networks, network pathology and computational chemotherapy
Signaling networks, network pathology and computational chemotherapy |
|
https://doi.org/10.18632/oncotarget.911
Kwang-Hyun Cho
|
| 178-179 |
Allosteric activation of PI3Kα by oncogenic mutations
Allosteric activation of PI3Kα by oncogenic mutations |
|
https://doi.org/10.18632/oncotarget.913
John E Burke,
Olga Perisic,
and Roger L Williams
|
| 180-181 |
Microbial Oncotarget: Bacterial-Produced Butyrate, Chemoprevention and Warburg Effect
Microbial Oncotarget: Bacterial-Produced Butyrate, Chemoprevention and Warburg Effect |
|
https://doi.org/10.18632/oncotarget.915
Dallas R. Donohoe,
Kaitlin P. Curry,
and Scott J. Bultman
|
| 182-183 |
Calcein-effluxing human colon cancer cells are enriched for self-renewal capacity and depend on β-catenin
Calcein-effluxing human colon cancer cells are enriched for self-renewal capacity and depend on β-catenin |
|
https://doi.org/10.18632/oncotarget.883
Joshua E. Allen,
and Wafik S. El-Deiry
|
| 184-191 |
HPV16 E5 and KGFR/FGFR2b interplay in differentiating epithelial cells
HPV16 E5 and KGFR/FGFR2b interplay in differentiating epithelial cells |
|
https://doi.org/10.18632/oncotarget.803
Valeria Purpura,
Francesca Belleudi,
Silvia Caputo,
and Maria Rosaria Torrisi
|
| 192-205 |
TRAIL induces apoptosis in oral squamous carcinoma cells: a crosstalk with oncogenic Ras regulated cell surface expression of death receptor 5
TRAIL induces apoptosis in oral squamous carcinoma cells: a crosstalk with oncogenic Ras regulated cell surface expression of death receptor 5 |
|
https://doi.org/10.18632/oncotarget.813
Jun-jie Chen,
Constantinos M. Mikelis,
Yaqin Zhang,
J. Silvio Gutkind,
and Baolin Zhang
|
| 206-217 |
Targeted alpha-therapy using [Bi-213]anti-CD20 as novel treatment option for radio- and chemoresistant non-Hodgkin lymphoma cells
Targeted alpha-therapy using [Bi-213]anti-CD20 as novel treatment option for radio- and chemoresistant non-Hodgkin lymphoma cells |
|
https://doi.org/10.18632/oncotarget.817
Mareike Roscher,
Inis Hormann,
Oliver Leib,
Sebastian Marx,
Josue Moreno,
Erich Miltner,
and Claudia Friesen
|
| 218-230 |
Comedo-DCIS is a precursor lesion for basal-like breast carcinoma: identification of a novel p63/Her2/neu expressing subgroup
Comedo-DCIS is a precursor lesion for basal-like breast carcinoma: identification of a novel p63/Her2/neu expressing subgroup |
|
https://doi.org/10.18632/oncotarget.818
Malathy PV Shekhar,
Ikuko Kato,
Pratima Nangia-Makker,
and Larry Tait
|
| 231-241 |
In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma
In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma |
|
https://doi.org/10.18632/oncotarget.820
Maria Teresa Di Martino,
Annamaria Gullà,
Maria Eugenia Gallo Cantafio,
Marta Lionetti,
Emanuela Leone,
Nicola Amodio,
Pietro Hiram Guzzi,
Umberto Foresta,
Francesco Conforti,
Mario Cannataro,
Antonino Neri,
Antonio Giordano,
Pierosandro Tagliaferri,
and Pierfrancesco Tassone
|
| 242-255 |
Ras inhibition boosts galectin-7 at the expense of galectin-1 to sensitize cells to apoptosis
Ras inhibition boosts galectin-7 at the expense of galectin-1 to sensitize cells to apoptosis |
|
https://doi.org/10.18632/oncotarget.844
Batya Barkan,
Adrienne D. Cox,
and Yoel Kloog
|
| 256-268 |
Preclinical analyses of intravesical chemotherapy for prevention of bladder cancer progression
Preclinical analyses of intravesical chemotherapy for prevention of bladder cancer progression |
|
https://doi.org/10.18632/oncotarget.852
Joan C Delto,
Takashi Kobayashi,
Mitchell C Benson,
James McKiernan,
and Cory Abate-Shen
|
| 269-276 |
Efemp1 and p27Kip1 modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models
Efemp1 and p27Kip1 modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models |
|
https://doi.org/10.18632/oncotarget.859
Diersch Sandra,
Patrick Wenzel,
Melanie Szameitat,
Philipp Eser,
Mariel C Paul,
Barbara Seidler,
Stefan Eser,
Marlena Messer,
Maximilian Reichert,
Philipp Pagel,
Irene Esposito,
Roland M Schmid,
Dieter Saur,
and Günter Schneider
|
| 277-288 |
TAp73β-mediated suppression of cell migration requires p57Kip2 control of actin cytoskeleton dynamics
TAp73β-mediated suppression of cell migration requires p57Kip2 control of actin cytoskeleton dynamics |
|
https://doi.org/10.18632/oncotarget.833
Johanna Rodhe,
Edel Kavanagh,
and Bertrand Joseph
|
| 289-297 |
DNA-intercalators Causing Rapid Re-expression of Methylated and Silenced Genes in Cancer Cells
DNA-intercalators Causing Rapid Re-expression of Methylated and Silenced Genes in Cancer Cells |
|
https://doi.org/10.18632/oncotarget.863
M. Zulfiquer Hossain,
Megan A. Healey,
Calvin Lee,
Weijie Poh,
Sashidhar R. Yerram,
Kalpesh Patel,
Nilofer S. Azad,
James G. Herman,
and Scott E. Kern
|
| 298-309 |
BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance
BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance |
|
https://doi.org/10.18632/oncotarget.864
Gerald S. Falchook,
Jonathan C. Trent,
Michael C. Heinrich,
Carol Beadling,
Janice Patterson,
Christel C. Bastida,
Samuel C. Blackman,
and Razelle Kurzrock
|
| 310-315 |
Growth of poorly differentiated endometrial carcinoma is inhibited by combined action of medroxyprogesterone acetate and the Ras inhibitor Salirasib
Growth of poorly differentiated endometrial carcinoma is inhibited by combined action of medroxyprogesterone acetate and the Ras inhibitor Salirasib |
|
https://doi.org/10.18632/oncotarget.867
Raya Faigenbaum,
Roni Haklai,
Gilad Ben-Baruch,
and Yoel Kloog
|
| 316-328 |
Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1)
Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1) |
|
https://doi.org/10.18632/oncotarget.834
Kristen M. Reipas,
Jennifer H. Law,
Nicole Couto,
Sumaiya Islam,
Yvonne Li,
Huifang Li,
Artem Cherkasov,
Karen Jung,
Amarpal S. Cheema,
Steven J.M. Jones,
John A. Hassell,
and Sandra E. Dunn
|
| 329-345 |
Mesenchymal stem cells deliver synthetic microRNA mimics to glioma cells and glioma stem cells and inhibit their cell migration and self-renewal
Mesenchymal stem cells deliver synthetic microRNA mimics to glioma cells and glioma stem cells and inhibit their cell migration and self-renewal |
|
https://doi.org/10.18632/oncotarget.868
Hae-Kyung Lee,
Susan Finniss,
Simona Cazacu,
Efrat Bucris,
Amotz Ziv-Av,
Cunli Xiang,
Kevin Bobbitt,
Sandra Rempel,
Laura Hasselbach,
Tom Mikkelsen,
Shimon Slavin,
and Chaya Brodie
|
| 346-361 |
Actin-binding protein alpha-actinin 4 (ACTN4) is a transcriptional co-activator of RelA/p65 sub-unit of NF-kB.
Actin-binding protein alpha-actinin 4 (ACTN4) is a transcriptional co-activator of RelA/p65 sub-unit of NF-kB. |
|
https://doi.org/10.18632/oncotarget.901
Vasilisa Aksenova,
Lidia Turoverova,
Mikhail Khotin,
Karl-Eric Magnusson,
Eugene Tulchinsky,
Gerry Melino,
George P Pinaev,
Nikolai Barlev,
and Dmitri Tentler
|
| 362-373 |
